WSL
TRML

Western Standard LLC’s Tourmaline Bio TRML Stock Holding History

Western Standard LLC’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-58,648
Closed -$1.1M – 43
2023
Q1 		$1.1M Buy
+58,648
New +$967K 1.12% 20

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Western Standard LLC's TRML Position: Q2 2023 in Review

Western Standard LLC sold out of Tourmaline Bio (TRML) in Q2 2023, closing a stake of 58,648 shares — an estimated $1.1M sold.

Western Standard LLC first reported a position in TRML in Q1 2023 and held it in 1 quarter. The position peaked at $1.1M in Q1 2023. 58 funds tracked by Wall St. Rank hold TRML as of Q2 2023.

  • Western Standard LLC reported no remaining Tourmaline Bio position as of Q2 2023 after selling out during the quarter.
  • Western Standard LLC sold 58,648 Tourmaline Bio shares in Q2 2023, an estimated $1.1M.
  • Western Standard LLC first reported a position in Tourmaline Bio in Q1 2023 and held it in 1 quarter.
  • Western Standard LLC's Tourmaline Bio position peaked at $1.1M in Q1 2023.
  • 58 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2023.

Based on Western Standard LLC's 13F filing for Q2 2023, filed 14 Aug 2023.